Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma
Background: Monoclonal antibodies (mAbs) targeting negative regulators, or checkpoint molecules (e.g. PD1/PD-L1 & CTLA4), of anti-tumoural T cells have demonstrated clinical efficacy in treating several neoplastic diseases. While many patients enjoy remarkable responses to checkpoint inhibitors,...
Main Authors: | Gayathri Vijayakumar, Peter Palese, Peter H. Goff |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-11-01
|
Series: | EBioMedicine |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352396419307029 |
Similar Items
-
Evaluation of Newcastle disease virus as an oncolytic agent in colorectal cancer cell lines
by: Chia, Suet Lin
Published: (2012) -
Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials
by: June Kyu Hwang, et al.
Published: (2020-11-01) -
Oncolytic Viruses and Immune Checkpoint Inhibitors: The “Hot” New Power Couple
by: Charlotte Lovatt, et al.
Published: (2023-08-01) -
Radioenhancement with the Combination of Docetaxel and Ultrasound Microbubbles: In Vivo Prostate Cancer
by: Firas Almasri, et al.
Published: (2023-05-01) -
Oncolytic adenoviruses expressing checkpoint inhibitors for cancer therapy
by: Daoyuan Xie, et al.
Published: (2023-11-01)